Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RASSF8 antisense RNA 1 (RASSF8-AS1) is a long non-coding RNA transcript located on chromosome 12, opposite to the RASSF8 coding gene[3]. It is regulated as an antisense RNA and may bind and modulate RASSF8 mRNA, either promoting its degradation or inhibiting its translation, thus influencing RASSF8 protein levels in cells[5]. RASSF8-AS1 is upregulated in esophageal squamous cell carcinoma, where it appears to play an oncogenic role and serves as a sensitive and specific blood exosomal biomarker for diagnosing and predicting prognosis in ESCC[2][4]. Its increased expression correlates with tumor progression and stage[2]. The transcript impacts cell proliferation, tumor immunity, and metabolism, but no drugs are currently known to target it directly. There are no reported adverse safety findings or therapeutic liabilities associated with RASSF8-AS1. Its role is principally as a modulator of tumor suppressor activity, via its antisense interaction with RASSF8 mRNA, and as a non-invasive biomarker in oncology[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RASSF8 antisense RNA 1 (RASSF8-AS1).